GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroBiologics Inc (NAS:FBLG) » Definitions » Other Current Assets

FBLG (FibroBiologics) Other Current Assets : $0.37 Mil (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is FibroBiologics Other Current Assets?

FibroBiologics's other current assets for the quarter that ended in Sep. 2024 was $0.37 Mil.

FibroBiologics's quarterly other current assets declined from Mar. 2024 ($0.76 Mil) to Jun. 2024 ($0.54 Mil) and declined from Jun. 2024 ($0.54 Mil) to Sep. 2024 ($0.37Mil).

FibroBiologics's annual other current assets declined from Dec. 2021 ($0.06 Mil) to Dec. 2022 ($0.06 Mil) declined from Dec. 2022 ($0.06 Mil) to Dec. 2023 ($0.05 Mil).


FibroBiologics Other Current Assets Historical Data

The historical data trend for FibroBiologics's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroBiologics Other Current Assets Chart

FibroBiologics Annual Data
Trend Dec21 Dec22 Dec23
Other Current Assets
0.06 0.06 0.05

FibroBiologics Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.15 0.05 0.76 0.54 0.37

FibroBiologics Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


FibroBiologics Other Current Assets Related Terms

Thank you for viewing the detailed overview of FibroBiologics's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


FibroBiologics Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
455 E. Medical Center Boulevard, Suite 300, Houston, TX, USA, 77598
FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.